Back to AKBAView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA4/24/2023
Vafseo
Vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
Erythropoiesis-Stimulating Agent (ESA)Phase 3
Anemia of Chronic Kidney Disease
Mircera®Phase 3
Anemia Associated With Chronic Kidney Disease (CKD)
Darbepoetin alfaPhase 3
Anemia
PraliciguatPhase 2
Focal Segmental Glomerulosclerosis
IW-1973Phase 2
Heart Failure With Preserved Ejection Fraction
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts